A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

450

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

September 22, 2027

Study Completion Date

December 30, 2027

Conditions

CancerPDACCRC (Colorectal Cancer)NSCLC

Interventions

DRUG

GFH276

GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Trial Locations (1)

Sun-Yat sen university cancer center, Guangzhou

All Listed Sponsors

lead

Genfleet Therapeutics (Shanghai) Inc.

INDUSTRY